Infliximab use in Crohn's disease: impact on health care resources in the UK.
OBJECTIVE: To quantify the impact of infliximab therapy on health care resource utilization in the UK. METHODS: A retrospective audit was undertaken at seven centres in the UK, which reviewed patient notes for a period of 6 months before and 6 months after an initial infliximab infusion. Details of...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|
| _version_ | 1826264415331155968 |
|---|---|
| author | Jewell, D Satsangi, J Lobo, A Probert, C Forbes, A Ghosh, S Shaffer, J Frenz, M Drummond, H Troy, G Turner, S Younge, L Evans, L Moosa, M Rodgers-Gray, B Buchan, S |
| author_facet | Jewell, D Satsangi, J Lobo, A Probert, C Forbes, A Ghosh, S Shaffer, J Frenz, M Drummond, H Troy, G Turner, S Younge, L Evans, L Moosa, M Rodgers-Gray, B Buchan, S |
| author_sort | Jewell, D |
| collection | OXFORD |
| description | OBJECTIVE: To quantify the impact of infliximab therapy on health care resource utilization in the UK. METHODS: A retrospective audit was undertaken at seven centres in the UK, which reviewed patient notes for a period of 6 months before and 6 months after an initial infliximab infusion. Details of hospital admissions, outpatient visits, operations, diagnostic procedures, drug usage, and overall efficacy were collected. Results were compared for the two 6 month study periods. RESULTS: A total of 205 patients (62% female, median age 33 years) with moderate/severe Crohn's disease were audited. The majority of patients had chronic active disease (62%) and most received one infusion initially (72%). Clinicians rated 74% of responses as good to excellent and patients 72%. Most patients had concomitant immunosuppression (pre: 75%, post: 75%). Approximately half of the patients (45%) stopped taking steroids, with a further 34% having a dosage reduction. A fall of 1093 inpatient days was seen (1435 vs. 342) in the 6 months following infliximab administration. There were seven fewer operations, 33 fewer examinations under anaesthetic, and 99 fewer diagnostic procedures. Outpatient visits were similar pre- versus post- (555 vs. 534). The total reduction in direct costs amounted to an estimated pounds 591,006. Three hundred and fifty-three infliximab infusions were administered at an estimated cost of pounds 562,719. Thus, there was a net reduction of pounds 28,287 or pounds 137.98 per patient. CONCLUSIONS: Infliximab appears to be a potentially cost effective treatment for selected patients based on the reduced number of inpatient stays, examinations under anaesthetic, and diagnostic procedures over a 6 month period. |
| first_indexed | 2024-03-06T20:07:25Z |
| format | Journal article |
| id | oxford-uuid:295d7de6-863a-4edc-a2f5-368fca49dace |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:07:25Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:295d7de6-863a-4edc-a2f5-368fca49dace2022-03-26T12:18:51ZInfliximab use in Crohn's disease: impact on health care resources in the UK.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:295d7de6-863a-4edc-a2f5-368fca49daceEnglishSymplectic Elements at Oxford2005Jewell, DSatsangi, JLobo, AProbert, CForbes, AGhosh, SShaffer, JFrenz, MDrummond, HTroy, GTurner, SYounge, LEvans, LMoosa, MRodgers-Gray, BBuchan, S OBJECTIVE: To quantify the impact of infliximab therapy on health care resource utilization in the UK. METHODS: A retrospective audit was undertaken at seven centres in the UK, which reviewed patient notes for a period of 6 months before and 6 months after an initial infliximab infusion. Details of hospital admissions, outpatient visits, operations, diagnostic procedures, drug usage, and overall efficacy were collected. Results were compared for the two 6 month study periods. RESULTS: A total of 205 patients (62% female, median age 33 years) with moderate/severe Crohn's disease were audited. The majority of patients had chronic active disease (62%) and most received one infusion initially (72%). Clinicians rated 74% of responses as good to excellent and patients 72%. Most patients had concomitant immunosuppression (pre: 75%, post: 75%). Approximately half of the patients (45%) stopped taking steroids, with a further 34% having a dosage reduction. A fall of 1093 inpatient days was seen (1435 vs. 342) in the 6 months following infliximab administration. There were seven fewer operations, 33 fewer examinations under anaesthetic, and 99 fewer diagnostic procedures. Outpatient visits were similar pre- versus post- (555 vs. 534). The total reduction in direct costs amounted to an estimated pounds 591,006. Three hundred and fifty-three infliximab infusions were administered at an estimated cost of pounds 562,719. Thus, there was a net reduction of pounds 28,287 or pounds 137.98 per patient. CONCLUSIONS: Infliximab appears to be a potentially cost effective treatment for selected patients based on the reduced number of inpatient stays, examinations under anaesthetic, and diagnostic procedures over a 6 month period. |
| spellingShingle | Jewell, D Satsangi, J Lobo, A Probert, C Forbes, A Ghosh, S Shaffer, J Frenz, M Drummond, H Troy, G Turner, S Younge, L Evans, L Moosa, M Rodgers-Gray, B Buchan, S Infliximab use in Crohn's disease: impact on health care resources in the UK. |
| title | Infliximab use in Crohn's disease: impact on health care resources in the UK. |
| title_full | Infliximab use in Crohn's disease: impact on health care resources in the UK. |
| title_fullStr | Infliximab use in Crohn's disease: impact on health care resources in the UK. |
| title_full_unstemmed | Infliximab use in Crohn's disease: impact on health care resources in the UK. |
| title_short | Infliximab use in Crohn's disease: impact on health care resources in the UK. |
| title_sort | infliximab use in crohn s disease impact on health care resources in the uk |
| work_keys_str_mv | AT jewelld infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT satsangij infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT loboa infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT probertc infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT forbesa infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT ghoshs infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT shafferj infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT frenzm infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT drummondh infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT troyg infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT turners infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT youngel infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT evansl infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT moosam infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT rodgersgrayb infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk AT buchans infliximabuseincrohnsdiseaseimpactonhealthcareresourcesintheuk |